Review





Similar Products

95
Novus Biologicals fancd2
MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and <t>FANCD2)</t> and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.
Fancd2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fancd2+antibody+-+bsa+free/FANCD2+Antibody+-+BSA+Free/pmc13650023-29-113-115
Average 95 stars, based on 1 article reviews
fancd2 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Novus Biologicals nb 100 182 rrid ab 350110
MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and <t>FANCD2)</t> and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.
Nb 100 182 Rrid Ab 350110, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fancd2+antibody+-+bsa+free/FANCD2+Antibody+-+BSA+Free/pmc12860730-10-7-4
Average 95 stars, based on 1 article reviews
nb 100 182 rrid ab 350110 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Novus Biologicals rabbit anti fancd2 antibody
(A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of <t>FANCD2</t> monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.
Rabbit Anti Fancd2 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fancd2+antibody+-+bsa+free/FANCD2+Antibody+-+BSA+Free/bio_rxiv__64898__2026__02__04__703705-167-13-16
Average 95 stars, based on 1 article reviews
rabbit anti fancd2 antibody - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Novus Biologicals anti fancd2
(A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of <t>FANCD2</t> monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.
Anti Fancd2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fancd2+antibody+-+bsa+free/FANCD2+Antibody+-+BSA+Free/bio_rxiv__64898__2025__12__17__694873-205-30-31
Average 95 stars, based on 1 article reviews
anti fancd2 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
Novus Biologicals rabbit anti fancd2
(A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of <t>FANCD2</t> monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.
Rabbit Anti Fancd2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fancd2+antibody+-+bsa+free/FANCD2+Antibody+-+BSA+Free/pm41309571-471-66-67
Average 95 stars, based on 1 article reviews
rabbit anti fancd2 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and FANCD2) and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.

Journal: Advanced Science

Article Title: Alkylating Agent–Induced FANCL Impairment Damages Pulmonary Arterial, Venous, and Microvascular Endothelial Cells and Predisposes to PAH/PVOD

doi: 10.1002/advs.78081

Figure Lengend Snippet: MMC or CDDP Treatment Induces Progressive DNA Damage Accumulation in Pulmonary Vascular Endothelium. (A–H) Immunoblots and analyzed graphs showing the γ‐H2AX protein expression in the lung tissue of rats treated with MMC (3 mg/kg, once weekly) for 2 or 4 weeks (A–D), and CDDP (4 mg/kg, once weekly) for 2 or 4 weeks (E–H). n = 6–12 rats per group. Protein expression levels were calculated as the ratio of the target protein band intensity to that of β‑actin and were normalized to the mean values of the respective 2‑week or 4‑week NC groups, expressed as fold change. (I, J) Immunohistochemical staining for the FA core factors (FANCL and FANCD2) and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 2 or 4 weeks, followed by quantification of the percentage of positive cells within the pulmonary vasculature. n = 6 rats per group. (K, L) Immunofluorescence staining for the endothelial cell marker vWF and the DNA damage marker γ‐H2AX in lung sections from rats treated with MMC (3 mg/kg, once weekly) or CDDP (4 mg/kg, once weekly) for 4 weeks, followed by correlation analysis between γ‐H2AX fluorescence intensity within vWF‑positive regions and vessel wall area percentage. n = 6 rats per group, with 10–25 vessels analyzed per group. Data are presented as mean ± SD. Differences between two groups were analyzed by t ‐test for C (FANCD2, FANCL), D (all panels), G (FANCD2, γ‐H2AX), H (all panels), and L (CDDP), Mann‐Whitney U‐test for C (γ‐H2AX), D (PCNA), G (FANCL), and L (MMC), or one‐way ANOVA with Tukey's honestly significant difference (Tukey's HSD) post hoc test for J. A value of P < 0.05 is considered statistically significant, n.s. indicates no statistical significance. Scale bar = 50 µm in I and 25 µm in K. NC: normal control.

Article Snippet: Primary antibodies for fibronectin (FN, #15613‐I‐AP, Proteintech, Rosemont, IL, USA), Twist (ab50887, Abcam, Cambridge, MA, USA), Vimentin (#5741, Cell Signaling Technology, Danvers, MA, USA), Snail (#ab53519, Abcam, Cambridge, MA, USA), ZO‐1 (21773‐1‐AP, proteintech, Wuhan, China), VEGFR2 (9698, CST, Boston, USA), Slug (YM8357, Immunoway, California, USA), proliferating cell nuclear antigen (PCNA, ab29, Abcam, Cambridge, MA, USA), CD31 (AF3628, R&D Systems, Minneapolis, MN, USA), Cleaved caspase3 (#9664, Cell Signaling Technology, Danvers, MA, USA), Bax (#2772S, Cell Signaling Technology, Danvers, MA, USA), B‐cell lymphoma/leukemia 2 (Bcl‐2, 13–8800, Thermo Fisher Scientific, Rockford, IL, USA), γ‐H2AX (#05‐635, EMD Millipore/Merck, USA), α‐smooth muscle actin (α‐SMA, ab124964 and ab7817, Abcam, Cambridge, MA, USA), FANCL (LS‐C807939, LifeSpan BioSciences, Seattle, WA, USA), FANCD2 (NB100‐182, Novus Biologicals, USA), general control nonderepressible 2 (GCN2, #46041, Cell Signaling Technology, Danvers, MA, USA), and β‐actin (66009‐1‐Ig, Proteintech, Rosemont, IL, USA) were used for immunoblotting, immunofluorescence (IF), and immunohistochemistry (IHC) staining.

Techniques: Western Blot, Expressing, Tissue, Immunohistochemical staining, Staining, Marker, Immunofluorescence, Analysis, Fluorescence, MANN-WHITNEY, Control

(A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of FANCD2 monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.

Journal: bioRxiv

Article Title: Aurora kinase A is a synthetic lethal target in FANCA-deficient cancers

doi: 10.64898/2026.02.04.703705

Figure Lengend Snippet: (A) Western blot illustrating FANCA protein loss in FANCA-deficient cell lines. (B,C) Lack of FANCD2 monoubiquitination, a hallmark of FA pathway activation, in FANCA-deficient cells. (D,E) FANCA-deficient cells show increased vulnerability to MMC: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (D) and DU145 WT vs DU145_ FANCA KO (E) are illustrated. (F,G) FANCA-deficient cells show increased vulnerability to cisplatin: drug response curves for CCH-SCC-FA1 ( FANCA -/- ) vs CCH-SCC-FA1 ( FANCA Compl ) (F) and DU145 WT vs DU145_ FANCA KO (G) are illustrated.

Article Snippet: Cells were then incubated with the primary antibody for 1 hour at RT, rabbit anti-FANCD2 antibody (Novus Biologicals, NB100-182, 1:500 in SB) or mouse anti-FANCD2 antibody (Novus Biologicals, NB100-316, 1:500 in SB).

Techniques: Western Blot, Activation Assay

Cells were exposed to 1 µM MMC for 24 hours vs control conditions (DMSO) and imaged via confocal microscopy using Zeiss LSM 710 or Zeiss LSM 980 (63x). (A,C,E) Representative immunofluorescence images for CCH-SCC-FA1 ( FANCA Compl ) vs CCH-SCC-FA1 ( FANCA -/- ) (A), DU145 WT vs DU145_ FANCA KO (C), and RPE1 WT vs RPE1_ FANCA KD (E); scale represents 20 µm. (B, D, F) FANCD2 foci quantification for the same FANCA-deficient vs proficient cell lines. The number of foci per cell are represented, and statistical significance was calculated with the unpaired t-test.

Journal: bioRxiv

Article Title: Aurora kinase A is a synthetic lethal target in FANCA-deficient cancers

doi: 10.64898/2026.02.04.703705

Figure Lengend Snippet: Cells were exposed to 1 µM MMC for 24 hours vs control conditions (DMSO) and imaged via confocal microscopy using Zeiss LSM 710 or Zeiss LSM 980 (63x). (A,C,E) Representative immunofluorescence images for CCH-SCC-FA1 ( FANCA Compl ) vs CCH-SCC-FA1 ( FANCA -/- ) (A), DU145 WT vs DU145_ FANCA KO (C), and RPE1 WT vs RPE1_ FANCA KD (E); scale represents 20 µm. (B, D, F) FANCD2 foci quantification for the same FANCA-deficient vs proficient cell lines. The number of foci per cell are represented, and statistical significance was calculated with the unpaired t-test.

Article Snippet: Cells were then incubated with the primary antibody for 1 hour at RT, rabbit anti-FANCD2 antibody (Novus Biologicals, NB100-182, 1:500 in SB) or mouse anti-FANCD2 antibody (Novus Biologicals, NB100-316, 1:500 in SB).

Techniques: Control, Confocal Microscopy, Immunofluorescence